What Are the Risks of HRT After 70?

Quick Summary

The main risks of HRT after 70 are higher cardiovascular danger, including blood clots and stroke, and breast cancer risk with combined therapy. A 2025 review concludes that starting menopausal hormone therapy at age 70 or older is not recommended because of higher cardiovascular risk.

  • A 2025 review does not recommend starting menopausal hormone therapy at age 70 or older.
  • Venous thromboembolism risk rises with age and when therapy is started later, per a 2020 guideline review.
  • Stroke risk depends on how therapy is delivered, so route and formulation matter.
  • Combined therapy is most consistently linked to breast cancer, based on observational evidence.
  • Ask a clinician which form is proposed, whether the uterus is present, and when the decision will be reassessed.

Table of Contents

What Are the Risks of HRT After 70?

Last Updated: November 5, 2026

Why Risk Changes With Age: Starting HRT After 65 or 70

Hormone replacement therapy (HRT) is not equally risky at every age. For women who begin HRT after 70, the risk profile is meaningfully different from what it looks like for a woman starting treatment in her early fifties. A 2025 review of menopausal hormone therapy concludes that initiating menopausal hormone therapy at age 70 or older is not recommended because of higher cardiovascular risk.

That conclusion is the central fact most readers need. The age at which therapy starts, and how long a woman has been without it, both shape the balance of benefit and harm. A 2020 guideline review of menopausal hormone therapy found that the risk of venous thromboembolism rises with age and when therapy is started later.

Age alone does not settle the question for everyone, however. Some women who already take HRT past 65 may be able to continue under medical supervision, a distinction covered below. For women considering a first course of therapy after 70, the evidence supports caution and a careful individual discussion with a clinician.

Blood Clots and Stroke: The Cardiovascular Risks of HRT After 70

Blood clots and stroke are the cardiovascular risks most often raised when HRT is discussed for older women. Venous thromboembolism, which includes deep vein clots and pulmonary embolism, is the clot risk specifically linked to hormone therapy. Stroke is the second concern, and it is the one most affected by how the therapy is delivered.

A 2025 review on hormone replacement therapy hazards identifies breast cancer, thrombosis and stroke as the principal hazards of hormone replacement therapy. The review does not give age-specific numerical estimates, so the size of the risk for an individual over 70 has to be assessed with a clinician who knows her medical history.

Cardiovascular disease, meaning heart and blood vessel disease, is also more common with age, which means a woman’s baseline risk is already higher before any hormone is added. That is why a medical history review, including prior clots, stroke and heart disease, sits at the center of any decision about HRT after 70.

How Route and Formulation Change Stroke Risk

Not all HRT carries the same stroke profile. Oral estrogen passes through the liver before reaching the bloodstream, which affects how clotting factors respond. Transdermal options bypass that first pass, which is one reason clinicians often weigh the route as carefully as the dose.

For a woman over 70, the route question is practical rather than academic. A clinician may consider a transdermal option when stroke or clot risk is a concern, though the choice depends on her health profile and symptoms. Any change in route should be made with medical guidance, not on the basis of a general article.

The main cardiovascular hazards of HRT after 70 are summarised below.

Risk What it involves Note
Venous thromboembolism Deep vein clots and pulmonary embolism Clot risk rises with age and later starts
Stroke Affected by how therapy is delivered Second key cardiovascular concern
Breast cancer Most consistently linked to combined therapy Observational evidence, not proof of cause
Baseline cardiovascular disease Heart and blood vessel disease More common with age, so baseline risk is higher

Breast Cancer and Other Cancer Risks in Older Women

Breast cancer is the risk most consistently associated with combined hormone therapy.

Those findings come from observational research, which shows association rather than proof of cause. Even so, they are the reason many clinicians treat a new cancer history, or a strong family history of breast cancer, as a serious factor in deciding against starting HRT late in life. Regular breast screening remains important for any woman on hormone therapy.

Estrogen After Age 70: Estrogen-Only Versus Combined Therapy

The type of therapy matters as much as the age at which it begins. Estrogen-only therapy is prescribed to women who have had a hysterectomy, because estrogen without a progestogen can thicken the uterine lining in a woman who still has her uterus. Combined estrogen-progestogen therapy protects the uterine lining in women who have not had a hysterectomy, and it is the form most strongly associated with breast cancer risk in the research above.

For women over 70, the choice between these two forms is a clinical decision that depends on whether the uterus is still present, symptoms, and overall risk. Neither form should be assumed safe or unsafe in general. Ask a clinician which form is proposed and why.

Continuing Treatment Versus Starting Late: Why the Distinction Matters

Most search results blur two very different clinical situations: a woman who started hormone therapy in her fifties and is still taking it past 70, and a woman who is considering a first course of therapy after 70. The evidence behind each is not the same, and the risk conversation should not be either.

Starting late. The clearest signal in the literature concerns initiation. A 2025 review of menopausal hormone therapy concludes that starting menopausal hormone therapy at age 70 or older is not recommended because of higher cardiovascular risk.

Book a consult →

Continuing. Continuation is a separate question. That statement is about women already established on treatment, often at a low dose, whose symptoms or bone protection still justify it.

A useful way to hold the distinction:

  • Why the therapy is being continued or started. Persistent vasomotor symptoms and bone protection are the two most common justifications in older women. If neither is present, the risk-benefit balance shifts toward stopping or not starting.
  • How long the woman has already been exposed. Duration of use matters for breast cancer risk in observational data, and a woman with 20 years of cumulative exposure is in a different position from a woman considering her first prescription.
  • What has changed since the original decision. New cardiovascular disease, a new cancer diagnosis, a clot, or a change in medicines can all tip the balance. Continuation should be periodically reassessed with a clinician.
  • Dose and route. Lowest effective dose and transdermal delivery are the levers clinicians most often use when continuing therapy in an older woman, because they may reduce some risks compared with standard oral doses.

Watch out: assuming that a clinician’s approval to continue HRT past 65 means the same therapy is appropriate indefinitely. Because changing health can also alter the balance of benefits and risks, include hormonal vaginal health in the issues you revisit with your clinician.

For a woman over 70 who has never used HRT, the practical takeaway is that the burden of justification is higher than for a long-term user. For a long-term user, the takeaway is that continuation is a legitimate option but not a default. Both conversations belong with a clinician who knows the full history.

Benefits of HRT After 70 and How to Weigh Them Against Risk

The main benefits of HRT in older women are relief of persistent menopausal symptoms, such as hot flashes and night sweats, and protection of bone density, which lowers fracture risk. Bone health matters more with age, because osteoporosis becomes more common after menopause. For some women with severe or persistent symptoms, the benefit side of the ledger can be substantial.

The weighing has to be individual. A woman with a clot history, active cardiovascular disease or a breast cancer history faces a very different calculation than a woman with few risk factors and disabling symptoms. Non-hormonal options exist for symptom relief, and a clinician may discuss other treatments for genitourinary symptoms. Both are worth raising with a clinician. You can explore more on this topic in our hormone replacement therapy for menopause symptoms guide.

Using an HRT Risk Calculator and Working Through Your Decision With a Doctor

Risk calculators are a conversation starter, not an answer. They estimate risk from age, health history, and therapy type, and they work best when a clinician reviews the output alongside symptoms, goals, and alternatives. For a woman over 70, the more useful exercise is a structured discussion that covers the same ground every time.

Doctor and patient reviewing clinical notes to discuss HRT after 70
Doctor and patient reviewing clinical notes to discuss HRT after 70

A practical checklist for the appointment:

  • Symptoms and goals. Which symptoms are driving the decision, hot flashes, night sweats, sleep disruption, genitourinary symptoms, bone protection, and how much do they interfere with daily life? Be specific about frequency and severity.
  • Uterus status. Whether the uterus is present determines whether a progestogen is needed and therefore whether combined therapy is on the table.
  • Cardiovascular history. Prior heart attack, stroke, transient ischemic attack, blood clot, atrial fibrillation, uncontrolled hypertension, or known vascular disease all weigh heavily against starting systemic therapy late.
  • Cancer history and family history. Personal history of breast cancer, endometrial cancer, or a strong family history of breast cancer changes the calculus, particularly for combined therapy.
  • Current medicines and supplements. Some interact with hormones or affect clotting risk; bring an actual list.
  • Alternatives already tried. Non-hormonal prescription options for vasomotor symptoms and low-dose vaginal estrogen for genitourinary symptoms are worth discussing before committing to systemic therapy.
  • Form, route, and dose. Ask which estrogen, which progestogen if any, and whether a transdermal option is appropriate given the stroke and clot concerns discussed above.
  • Reassessment schedule. Ask when the decision will be revisited and what would trigger an earlier review.

Monitoring and warning symptoms. Anyone on systemic HRT should know which symptoms warrant urgent attention rather than a routine call: sudden shortness of breath, chest pain, a swollen or painful leg, sudden severe headache, sudden vision change, weakness or numbness on one side, or a new breast lump.

What calculators can and cannot do. Tools that estimate breast cancer or cardiovascular risk are calibrated to populations, not individuals, and they do not account for every formulation or duration pattern. Treat the number as one input, not a verdict.

Several questions are worth asking directly: Which form and route are you proposing, and why? If you are weighing these options and want help with the process, our guide to understanding hormone panels for women explains the lab results your doctor may review, and you can find a doctor who listens to perimenopause concerns to start that conversation.

Frequently Asked Questions

Is 70 too old to start HRT?

Starting hormone replacement therapy at 70 or older is generally not recommended. A 2025 review notes that initiation at this age is not advised because of higher cardiovascular risk. Risk depends on your personal medical history, the formulation and route, and how long you plan to take it. A physician can review your individual profile, so speak with a qualified clinician before making any decision.

Can women over 70 safely continue hormone therapy?

Continuing therapy begun at an earlier age is a different question from starting it late. Continuation decisions should be individualized, reassessed regularly, and made with the lowest effective dose in mind. Discuss your history with your doctor to determine whether continued use fits your situation.

Does the route of HRT affect the risks after 70?

The route and formulation matter. Risk discussions therefore distinguish formulations rather than treating all HRT as equivalent. Dose and duration also shape the overall risk profile. Your clinician can compare options against your medical history and symptoms to find the approach that fits you best.

What are the symptoms of low estrogen in women over 70?

Low estrogen can contribute to symptoms such as vaginal dryness, bone loss, and changes in sleep and mood, though many of these overlap with other conditions common in later life. Because the symptoms are not specific, a clinician typically evaluates them alongside your history and, when appropriate, lab results. Do not assume a symptom is caused by estrogen levels without an evaluation. Book a consultation to get an accurate assessment.


Dr. Shweta Patel and the GAYA Wellness team work with women over 40 on hormone decisions grounded in their labs, symptoms and goals. If you are considering HRT, book a consult to talk through your individual risk profile with a clinician.

GoogleAdd gayawellness.com as a preferred source on Google →